share_log

PRE 14A: Preliminary proxy statements relating to merger or acquisition

PRE 14A: Preliminary proxy statements relating to merger or acquisition

PRE 14A：并购重组委托声明
美股SEC公告 ·  2024/12/20 11:22

Moomoo AI 已提取核心信息

ZyVersa Therapeutics is seeking stockholder approval to issue up to 1,637,000 shares of common stock upon exercise of warrants, in compliance with Nasdaq Listing Rule 5635(d). The warrants were issued on November 5, 2024, as part of an inducement offer to holders of existing warrants to exercise at a reduced price of $2.06 per share.The new Series A-2 warrants have a 5-year term and are exercisable at $2.06 per share, potentially raising $3.4 million if fully exercised. Approval is required as the potential share issuance exceeds 20% of outstanding stock. The company has agreed to hold a stockholder meeting by March 4, 2025 to obtain approval.If approved, the issuance could dilute existing shareholders' ownership. The warrants contain provisions that could discourage acquisition attempts. ZyVersa may be required to account for the warrants as liabilities, potentially impacting financial results.
ZyVersa Therapeutics is seeking stockholder approval to issue up to 1,637,000 shares of common stock upon exercise of warrants, in compliance with Nasdaq Listing Rule 5635(d). The warrants were issued on November 5, 2024, as part of an inducement offer to holders of existing warrants to exercise at a reduced price of $2.06 per share.The new Series A-2 warrants have a 5-year term and are exercisable at $2.06 per share, potentially raising $3.4 million if fully exercised. Approval is required as the potential share issuance exceeds 20% of outstanding stock. The company has agreed to hold a stockholder meeting by March 4, 2025 to obtain approval.If approved, the issuance could dilute existing shareholders' ownership. The warrants contain provisions that could discourage acquisition attempts. ZyVersa may be required to account for the warrants as liabilities, potentially impacting financial results.
ZyVersa Therapeutics正在寻求股东批准，发行多达1,637,000股普通股以履行认股权证，以符合纳斯达克上市规则5635(d)。这些认股权证于2024年11月5日发行，为现有认股权证持有者提供以每股2.06美元的降低价格行使权利的诱导优惠。新的A-2系列认股权证期限为5年，行使价格为每股2.06美元，如果全部行使，可能筹集340万美元。由于潜在的股份发行超过已发行股票的20%，因此需要获得批准。公司已同意在2025年3月4日前召开股东会议以获得批准。如果获得批准，发行可能会稀释现有股东的持股。认股权证中包含的条款可能会阻碍收购尝试。ZyVersa可能需要将这些认股权证视为负债，这可能会影响财务结果。
ZyVersa Therapeutics正在寻求股东批准，发行多达1,637,000股普通股以履行认股权证，以符合纳斯达克上市规则5635(d)。这些认股权证于2024年11月5日发行，为现有认股权证持有者提供以每股2.06美元的降低价格行使权利的诱导优惠。新的A-2系列认股权证期限为5年，行使价格为每股2.06美元，如果全部行使，可能筹集340万美元。由于潜在的股份发行超过已发行股票的20%，因此需要获得批准。公司已同意在2025年3月4日前召开股东会议以获得批准。如果获得批准，发行可能会稀释现有股东的持股。认股权证中包含的条款可能会阻碍收购尝试。ZyVersa可能需要将这些认股权证视为负债，这可能会影响财务结果。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Portage Biotech
    PRTG
    -- 9.600
    莱斯康制药
    LXRX
    -- 0.571
    DBV Technologies
    DBVT
    -- 6.200
    NeOnc Technologies
    NTHI
    -- 16.550
    Alumis
    ALMS
    -- 5.640
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    中概股财报季火热：惊喜盈利能否延续涨势？
    1. 哪些行业可能成为本轮中概股财报季的市场焦点？ 2. 在政府强调科技创新和可持续发展的背景下，你认为哪些行业具有最大的增长潜力？ 展开
    中国两会：会议前后股票价格走势的主要要点